Picture Berlin Partner Voices Peter Seeberger Chemistry Transformation 650x100px
Document › Details

Medigene AG. (2/2/17). "Press Release: Medigene Participates at Five National and International Conferences in February and March 2017". Martinsried.

Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 LSX Ltd. (Biotech and Money)
  Group Informa (Group) [NEW]
Products Product Biotech and Money 2017 London
  Product 2 T cell therapy
Persons Person Taapken, Thomas (InflaRx 202010– CFO before Imcyse + Medigene + Epigenomics + Biotie/elbion + DVC + Burrill)
  Person 2 Mayer, Robert (Medigene 201512– Senior Manager PR + IR before College Hill Life Sciences/Northbank Munich)

Medigene AG (FSE: MDG1, Prime Standard) announces its participation at five upcoming scientific, investor and business development conferences:

* Biotech and Money London
Date: 07 - 08 February 2017
Location: London, UK
Dr. Thomas Taapken, Medigene's CFO, will give a corporate presentation on 8th February at 9.25 am.

* ODDO 11th German Conference
Date: 15 - 16 February 2017
Location: Frankfurt, Germany

* International Symposium ACUTE LEUKEMIAS XVI
Date: 19 - 22 February 2017
Location: Munich, Germany

* 9th International Cellular Therapy Symposium
Date: 16 -17 March 2017
Location: Erlangen, Germany

* BIO-Europe Spring
Date: 20 - 23 March 2017
Location: Barcelona, Spain

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( We will then delete your address from our distribution list.

Record changed: 2023-06-05


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top